The Cameron Institute

Pharmaceutical Access in Least Developed Countries: on-the-ground barriers and industry successes

Today, The Cameron Institute released a report highlighting the importance of public-private partnerships and of intellectual property protections to improving global health. The evidence in this report strongly supports North-South, public-private partnerships as the preferred means by which to improve access to care and public health outcomes in least-developed countries. “Sustainable development

Summary Report – Benefit-Risk Roundtable

On Friday, March 5, 2010, over thirty Canadian health stakeholders (representing patients, providers, government, academics and industry) participated in a roundtable meeting to discuss the new paradigm of benefit-risk introduced in Bill C-51. The day featured a rich discussion (moderated by Dr. Stuart MacLeod) that effectively framed the issues in benefit-risk evaluation and set the stage for

Comments regarding coordination and strategic planning of the Federal Effort Against Intellectual Property Infringement

Comments submitted to the U.S. Intellectual Property Enforcement Coordinator (Office of Management and Budget, Executive Office of the President) as part of a public consultation on the costs and risks of IP infringement. Thank you for the opportunity to comment upon the Joint Strategic Plan designed to co- ordinate and bolster the Federal effort against the

Canadian Roundtable on Clinical Considerations for Subsequent Entry Biologics

Key learning points for physicians, pharmacists and patients. Following very active discussion of the issues noted above, the roundtable arrived at consensus on a number of critical points likely to define the continuing discussion about Health Canada’s guidelines for regulation of SEBs as noted below. 1)  Subsequent entry biologics, or biosimilars or follow-on biologics, are

From Boardroom to Bedside: How to Define and Measure Hospital Quality

Michael Heenan, Haajra Khan and Dorothy Binkley Article published in Healthcare Quarterly, Vol 13 No 1. Read full article

Quality health care?

Published in Opinion/Editorials – Bangor Daily News, Maine Monday, November 20, 2000 By Anthony Lordon While enterprising politicians and reporters make headlines by bashing the pharmaceutical industry or by escorting American seniors to Canada to buy “price-controlled” drugs, the real issue is being ignored: access to quality health care through appropriate coverage and reimbursement. American

Uncontrolled Spending Threatens Innovation

As proud as we are as Canadians, we and our European cousins must concede that the United States of America is the font of almost all the innovation that the world enjoys today. No where is this more true than in medicine. Almost all of the patented, innovative drugs that we use today have come

Evidence and Values: requirements for public reimbursement of drugs for rare diseases – a case study in oncology

Doubts have been expressed about whether standard methods of health technology assessment are suitable for the evaluation of drugs for rare diseases. Under conditions of rarity, it may be more difficult to conduct large randomized trials in order to gather adequate evidence on efficacy, and the standard methods of economic evaluation may not aserious and/or

We know with accuracy only when we know little

Our title reflects a maxim penned by Goethe. It continues in translation to read ‘With knowledge doubt increases.’1 The papers that appear in this issue stemming from a special symposium held in Banff, Alberta in February 2009, describe our progress toward agreement on the concept of access with evidence development (AED).2-6  Goethe’s reflection summarizes the dilemma. Much

Summary Report – PhRMA International Alliance Development Academic Roundtable

On Wednesday, August 19, 2009, fourteen academics from the U.S., Canada and the UK were joined by select PhRMA staff to participate in a PhRMA International Alliance Development Academic Roundtable. The discussion focused on the issues of biosimilars, also referred to as follow-on biologics (FOBs), health technology assessment (HTA), and intellectual property protection. Summary Report